Table 1.
Bivariable Comparisons in the Features of Incarcerated and Non-Incarcerated Interviewees
| Parameter | Total n (%) | Incarcerated n (%) | Not Incarcerated n (%) |
p-value |
|---|---|---|---|---|
| Sociodemographic features | ||||
| Gender | ||||
| Male | 239 (75.4) | 86 (89.6) | 153 (69.2) | < 0.001 |
| Female | 78 (24.6) | 10 (10.4) | 68 (30.8) | |
| Housing status | ||||
| Unstable | 117 (36.9) | 61 (63.5) | 56 (25.3) | < 0.001 |
| Stable | 200 (63.1) | 35 (36.5) | 165 (74.7) | |
| Level of education | ||||
| Primary | 27 (8.5) | 7 (7.3) | 20 (9.0) | 0.005 |
| Secondary | 223 (70.4) | 79 (82.3) | 144 (65.2) | |
| High school or higher | 67 (21.1) | 10 (10.4) | 57 (25.8) | |
| Current MOUD type | ||||
| BUP or BUP/NAL | 195 (61.5) | 59 (61.5) | 136 (61.5) | 0.989 |
| Methadone | 122 (38.5) | 37 (38.5) | 85 (38.5) | |
| Binarized answer to Q40. “Would you be prepared to change your current treatment in order to take this new treatment (ie XR-BUP)?” | ||||
| No, or do not know | 148 (46.7) | 35 (36.5) | 113 (51.1) | 0.016 |
| Yes | 169 (53.3) | 61 (63.5) | 108 (48.9) | |
| Binarized answers to Q38. “In your opinion, what are the important points that could lead you to choose this new treatment (ie XR-BUP)?” | ||||
| No longer having to take any tablets (or capsules/syrup) every day | ||||
| Not important | 86 (27.1) | 19 (19.8) | 67 (30.3) | 0.053 |
| Important | 231 (72.9) | 77 (80.2) | 154 (69.7) | |
| No longer forgetting to take the tablets (or capsules/syrup) | ||||
| Not important | 137 (43.2) | 43 (44.8) | 94 (42.5) | 0.709 |
| Important | 180 (56.8) | 53 (55.2) | 127 (57.5) | |
| The option of taking the medication only once a week/month | ||||
| Not important | 63 (19.9) | 17 (17.7) | 46 (20.8) | 0.524 |
| Important | 254 (80.1) | 79 (82.3) | 175 (79.2) | |
| The fact that a subcutaneous injection is involved (only slightly painful) | ||||
| Not important | 182 (57.4) | 75 (78.1) | 107 (48.4) | < 0.001 |
| Important | 135 (46.2) | 21 (21.9) | 114 (51.6) | |
| Being sure to receive a constant dose, always effective throughout the week/month | ||||
| Not important | 44 (13.9) | 6 (6.3) | 38 (17.2) | 0.010 |
| Important | 273 (86.1) | 90 (93.7) | 183 (82.8) | |
| No longer having to use heroin/morphine | ||||
| Not important | 67 (21.1) | 24 (25.0) | 43 (19.5) | 0.267 |
| Important | 250 (78.9) | 72 (75.0) | 178 (80.5) | |
| Avoiding having to share (or resell) all or part of my prescribed treatment | ||||
| Not important | 179 (56.5) | 60 (62.5) | 119 (53.8) | 0.153 |
| Important | 138 (43.5) | 36 (37.5) | 102 (46.2) | |
| No longer worrying about feeling ill if I forget my treatment for a few hours, or if I am unable to take it at the usual time | ||||
| Not important | 64 (20.2) | 26 (27.1) | 38 (17.2) | 0.044 |
| Important | 253 (79.8) | 70 (72.9) | 183 (82.8) | |
| No longer feeling the effect of heroin/morphine if I take more of this treatment than I should | ||||
| Not important | 148 (46.7) | 53 (55.2) | 95 (43.0) | 0.045 |
| Important | 169 (53.3) | 43 (44.8) | 126 (57.0) | |
| No longer having the option of injecting, snorting or inhaling my treatment | ||||
| Not important | 163 (51.4) | 58 (60.4) | 105 (47.5) | 0.035 |
| Important | 154 (48.6) | 38 (39.6) | 116 (52.5) | |
| The option of a more “discreet” treatment (one injection a week/month by going to my doctor’s/to the centre) as compared to tablets (or capsules, syrup) to be taken at home, with me, every day | ||||
| Not important | 108 (34.1) | 23 (24.0) | 85 (38.5) | 0.012 |
| Important | 209 (66.9) | 73 (76.0) | 136 (61.5) | |
Note: Significant p-values are presented in bold.
Abbreviations: BUP, buprenorphine; BUP/NAL, buprenorphine/naloxone; MOUD, medications for opioid use disorder; XR-BUP, Extended-release buprenorphine.